Information to investors

Inven2 wants to have a close dialogue with you as an investor and as someone who might have an interest in investing in and contributing to developing our active innovation projects. These are projects that we believe have the potential to become successful businesses

Each year, we evaluate around 100 new inventions. We proceed with around 30% of the proposals as active innovation projects in close cooperation with the inventors. Some inventions are obvious candidates for licencing to established industry, while others have the potential to become companies that develope products and services that can make an impact on the community at large.

Innovation projects that we believe are best developed through business start-ups need competent investors to join, maybe it is you?


Inven2 as a shareholder

Inven2’s purpose is to bring as many ideas from research to the market as possible. Sometimes this means that the development takes place in a startup company. Inven2 often invests to get such companies started and participates in share issues throughout the development phase; sometimes we also have founder shares. For such companies that grow and where the shares can be realized at some point, Inven2’s purpose means that we sell all or parts of our shareholding to invest in the establishment of new companies.


It is crucial to have sufficient capital turnover to assist in the commercialization process in several companies. A stock market listing will be considered a liquidity event for Inven2 and will therefore be used to realize 1/3 of the equity holdings in connection with a listing. As one of the first investors in a company, Inven2 will often need to also realize the remaining 2/3 earlier than many other investors who come in later.

Investment opportunities


Here is an overview of four of our most promising innovation projects at present. These are projects we consider to be suitable as business start-ups, and for which we are looking for investors.

Therapeutic regulation of WNT/YAP-signaling through a potent and specific tankyrase inhibitor

A class of novel WNT/YAP inhibitor compounds exhibiting high specificity for tankyrase and demonstrated proof of concept in mouse models for several cancer indications. Read More

AnaConDebt – Analysis of Contagious technical Debt

Technical debt in software development consists of sub-optimal design solutions that are beneficial in the short term, but create costly negative impact in the long run, e.g. costly maintenance changes and impossibility to evolve the system. Read More

Portfolio businesses

Portfolio businesses

Inven2 has a portfolio comprising 50 companies. We have established them either on our own or alongside investors and others. The point of departure for the companies are research results from innovative researchers. The portfolio value in December 2022 is NOK 11 billion, but this will vary with the value of the individual company and how long we are shareholders in the most valuable companies.